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Objectives: To determine if a specific intervention reduces the composite of progression of patients with COVID-
19-related disease to organ failure or death as measured by time to incidence of any one of the following: death,
invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure
(estimated Cockcroft Gault creatinine clearance <15ml/min).
Trial design: Randomised, parallel arm, open-label, adaptive platform Phase 2/3 trial of potential disease modifying
therapies in patients with late stage 1/stage 2 COVID-19-related disease, with a diagnosis based either on a positive
assay or high suspicion of COVID-19 infection by clinical, laboratory and radiological assessment.
Participants: Patients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease
(with/without a positive COVID-19 test) AND a risk count (as defined below) >3 OR ≥3 if risk count includes “Radio-
graphic severity score >3”. A risk count is calculated by the following features on admission (1 point for each): radio-
graphic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x109/L, age
>40 years and CRP >40 mg/L.
Patients should be considered an appropriate subject for intervention with immunomodulatory or other disease
modifying agents in the opinion of the investigator and are able to swallow capsules or tablets. The complete
inclusion and exclusion criteria as detailed in the Additional file 1 should be fulfilled. Drug specific inclusion and
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exclusion criteria will also be applied to the active arms. Patients will be enrolled prior to the need for invasive
mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres in the UK
including initially at Cambridge University Hospitals NHS Foundation Trust and St George’s University NHS
Foundation Trust. Other centres will be approached internationally in view of the evolving pandemic.
Intervention and comparator: There is increasing evidence of the role of immunomodulation in altering the
course of COVID-19. Additionally, various groups have demonstrated the presence of pulmonary shunting in pa-
tients with COVID-19 as well as other cardiovascular complications. TACTIC-E will assess the efficacy of the novel im-
munomodulatory agent EDP1815 versus the approved cardio-pulmonary drugs, Dapagliflozin in combination with
Ambrisentan versus the prevailing standard of care.
EDP1815 will be given as 2 capsules twice daily (1.6 x 1011 cells) for up to 7 days with the option to extend up to
14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically
responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment
course. Ambrisentan 5mg and Dapagliflozin 10mg will be given in combination once daily orally for up to
maximum of 14 days. Patients will be randomised in a 1:1:1 ratio across treatments. Each active arm will be
compared with standard of care alone. Additional arms may be added as the trial progresses. No comparisons will
be made between active arms in this platform trial.
Main outcomes: The primary outcome is the incidence (from baseline up to Day 14) to the occurrence of the any
one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation,
cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine
clearance <15ml/min).
Randomisation: Eligible patients will be randomised using a central web-based randomisation service (Sealed En-
velope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or standard of care.
Blinding (masking): This is an open-label trial. Data analysis will not be blinded.
Numbers to be randomised (sample size): There is no fixed sample size for this study. There will be an early
biomarker-based futility analysis performed at a point during the study. If this biomarker futility analysis is not con-
clusive, then a second futility analysis based on clinical endpoints will be performed after approximately 125 pa-
tients have been recruited per arm. Provisionally, further analyses of clinical endpoints will be performed after 229
patients per active arm and later 469 patients per arm have been recruited. Further additional analyses may be trig-
gered by the independent data monitoring committee.
Trial Status: TACTIC-E Protocol version number 1.0 date May 27th, 2020. Recruitment starts on the 3rd of July 2020.
The end trial date will be 18 months after the last patient’s last visit and cannot be accurately predicted at this time.
Trial registration: Registered on EU Clinical Trials Register EudraCT Number: 2020-002229-27 registered: 9 June
2020.
The trial was also registered on ClinicalTrials.gov (NCT04393246) on 19 May 2020.
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
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Additional file 1. Full Study Protocol.
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